| Literature DB >> 19540273 |
Sassan Noazin1, Ali Khamesipour, Lawrence H Moulton, Marcel Tanner, Kiumarss Nasseri, Farrokh Modabber, Iraj Sharifi, E A G Khalil, Ivan Dario Velez Bernal, Carlos M F Antunes, Peter G Smith.
Abstract
Despite decades of investigation in countries on three continents, an efficacious vaccine against Leishmania infections has not been developed. Although some indication of protection was observed in some of the controlled trials conducted with "first-generation" whole, inactivated Leishmania parasite vaccines, convincing evidence of protection was lacking. After reviewing all previously published or unpublished randomized, controlled field efficacy clinical trials of prophylactic candidate vaccines, a meta-analysis of qualified trials was conducted to evaluate whether there was some evidence of protection revealed by considering the results of all trials together. The findings indicate that the whole-parasite vaccine candidates tested do not confer significant protection against human leishmaniasis.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19540273 DOI： 10.1016/j.vaccine.2009.05.084
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641